Spectral AI Inc (MDAI)

$MDAI BARDA orders:
Regulatory Trigger: The funding to distribute these units was contingent upon U.S. regulatory clearance. Following Spectral AI’s FDA De Novo clearance in May 2026, the company is now legally authorized to initiate these placements.Dual-Use Mandate: The systems are being deployed for routine daily clinical use. However, the federal subsidy specifically secures them to act as a medical countermeasure for national emergency readiness during Burn Mass Casualty Incidents (BMCI).Expansion Potential: The initial 30 units serve as a commercial proof-of-concept. The contract contains provisions to potentially subsidize 140 additional systems across wider U.S. healthcare networks as adoption grows

🤡 lol

Key 2026 Operational and Business Achievements

Received FDA clearance for the DeepView System for Burn Indication; with this classification, Spectral AI is now authorized to commence commercial distribution activities in the United States.
Awarded $31.7 million of advanced funding from the Biomedical Advanced Research and Development Authority (“BARDA”) to accelerate and support additional feature aspects for the DeepView System.
Expanded leadership team in advance of commercial activities, including the recent appointment of David McGuire as Chief Financial Officer.
Delivered a fully functioning prototype of our Deep View System handheld device under our Department of Defense contract through the contracting consortium called MTEC.
Finalized the development of the Outcome Study, which will focus on the benefits derived from the use of the DeepView System across clinician workflows and patients’ journeys with an intended scope of approximately 286 patients spread across 12 clinical sites.
Showcased the DeepView System at this year’s Annual Meeting of the American Burn Association (“ABA”), which included an overview of the technology to attendees at the ABA Innovation Theater.
Received the “Small Business Innovator Award” at the inaugural Texas Innovation Conference, which was held in April 22-23, 2026 at the campus of Texas Christian University.

Anticipated Operational and Commercial Milestones

Generate first-ever commercial sales of the DeepView System by year end 2026:
United States: Phase II of our contract with BARDA includes funding for the procurement of up to 30 DeepView System devices in burn centers and level one trauma centers and emergency departments across the United States.
International: We anticipate initial sales in the UK, Australia or the Gulf Cooperation Council nations by the fourth quarter of 2026 following an update to our UKCA authorization (initially obtained in 2024) to reflect the characteristics of the DeepView System as cleared by the FDA.
Continue to strengthen executive and sales team by filling key positions to support the commercial roll out of the DeepView System.
Initiate Outcome Study in the fourth quarter of 2026. The Study is designed to demonstrate the surgical precision that results from a wound assessment made by the DeepView System and how improved time to treatment decisions will beneficially impact a patient’s overall care journey.

$MDAI No, Spectral AI’s management likely could not have prevented the MDAI stock sell-off through PR timing or messaging alone, because the drop was primarily driven by structural financing constraints rather than negative market sentiment.

Following the May 26, 2026, announcement of the FDA De Novo classification for the DeepView System, MDAI shares dropped roughly 12%.While retail investors often view a drop on good news as a failure of management communication, the underlying mechanics reveal why altering the announcement strategy would have yielded little difference.

The Real Culprit: The Hudson Bay Overhang

The sell-off was not a "panic sell," but rather legal, programmatic selling tied to the company's structural financing.
https://stocktwits.com/cryptobythelake/message/654843213
cryptobythelake

Sour grapes Jimry?.. if late to the party raise a toast not some whine past it's due date :)
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=176624861

🤡 lol

☯️***From Barchart.....
***https://www.barchart.com/stocks/quotes/MDAI/overview

☯️***.https://nz.finance.yahoo.com ›

☯️***Stock Titan
***https://www.stocktitan.net › news

Most of the time these Barda recipients make money. A little sell off today which is expected and as many other AI platforms are getting whacked.
Looking to add on this dip.

Spectral AI Awarded $31.7 Million of BARDA Funding to Accelerate Development of the DeepView® System
DALLAS, March 18, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that it has received $31.7 million in funding from the Biomedical Advanced Research and Development Authority (“BARDA”) to accelerate and support additional feature aspects for the Company’s DeepView® System, its AI-driven burn wound imaging technology. As part of the ongoing partnership, Spectral AI has committed to provide an additional $9.7 million to the total overall development costs associated with these feature advancements.

This immediate, non-dilutive funding is being advanced in addition to the $54.9 million of funding committed to date as part of the Company’s current contract with BARDA (the “BARDA Contract”) valued up to $150.0 million, as the Company awaits a determination on market authorization from the U.S. Food and Drug Administration (FDA) for the DeepView System.

“We are pleased to continue our long-standing partnership with BARDA and are grateful for its ongoing support of the DeepView System, a diagnostic tool that empowers physicians to make quick, data-driven decisions that can improve patient outcomes,” said Vincent Capone, Chief Executive Officer of the Company. “Burn wound assessment is crucial in determining next-step treatment for patients, which currently largely relies on the clinical judgement of physicians. This unmet clinical need is dramatically magnified in the event of mass casualty burn incidents, or BMCIs, where the ability to triage burn patients rapidly and properly would be crucial in allocating valuable resources and managing the surgical burden. The DeepView System technology represents a new paradigm in the assessment of burn wounds and can provide meaningful clinical guidance to physicians in their diagnosis and treatment recommendations."

Interest around AI-driven healthcare names remains high, but this one still needs stronger proof points to separate signal from hype. The next set of updates will matter more than short-term price action.

10+

Where is this going

JP Morgan's Jaime Dimon nodding to Trump tariffs and overall economic policy. He just committed 1.5 Trillion bucks over the next ten years into critical metals admitting past policies put us in real danger depending on China!! Metals, AI and high tech related companies are on their list. $5 Billion annually in AI alone. As well JP Morgan is lowering interest rates...a shot in the ass for RE and consumer goods especially autos that have a huge pent up demand. Average car on the road is 13 years old ....considered super sluggish... lots of buying this end of 2025 with 2026 looking to be a super banner year. American economy next year will be on super steroids.

Super !

Yep--they are on the list

https://time.com/7318020/worlds-top-healthtech-companies-2025/

https://www.facebook.com/NHSEngland/posts/a-revolutionary-new-ai-tool-is-being-used-to-help-predict-the-healing-of-burn-in/1183385613816858/

I actually completed the plan in 10 (have a post somewhere lolz..) then blew it all on peeny stalks.. lucky I could afford some Spectral 🤑

Lol, you may have to change your plan to a 1.2 year plan!!

I have!!

Yeah, this ai space and world will look quite different in a few short years, gl..

Interesting. Perhaps if the FDA had some A.I. holes to look in they could do something correctly and timely.
What a world hey? Thanks.

Sometimes one feels like their cat or dog has them well trained. And, they're not as smart as A.I. [..the critters that is] . Throwing more animals into the mix,.. it feels like going down a rabbit hole - only it's an A.I. hole. Anthropomorphizing A.I. like we do animals you might say you're under the influence of an A.I.'s hole. It's ok. This is an A.I. company. Trading it is manipulated by A.I. market makers. And, to the point; discussion on these boards should be by robots. It may have been a bot that generated this query bout' travel plans for MDAI'$ trip to the moon:

cryptobythelake Yesterday 8:53 AM
$MDAI I asked ChatGPT to give me a SAI....... Catalyst Calendar (next 12–18 months)
Date / Horizon Catalyst Impact Q3–Q4 2025
FDA De Novo review ongoing (DeepView Burn) Binary event — first predictive burn tool in U.S.
Late 2025 Updates from UKCA deployments Early traction, health economics data 2025–2026
BARDA contract milestones ($149M potential)
Non-dilutive funding + validation 2025–2026
SnapShot M (handheld) military development
Expands TAM (battlefield, EMS) Anytime Financing/strategic partnership Critical for U.S. launch readiness

UKCA deployments Early traction, health economics data

What does this statement have to do with MDAI.. "UKCA deployments Early traction, health economics data .." ?.
Great question—this statement touches on several key themes that are directly relevant to Medical Device AI (MDAI). Let’s break it down:

🧠 What the Statement Means
UKCA deployments: Refers to medical devices (including AI-based ones) being approved and launched under the UK Conformity Assessed (UKCA) marking system, which is the UK’s post-Brexit equivalent of the CE mark.

Early traction: Suggests that these devices—likely including MDAI solutions—are gaining initial market acceptance or clinical adoption.

Health economics data: Indicates that data is being collected to demonstrate the value of these technologies in terms of cost-effectiveness, outcomes, and system-wide impact.

🔗 How It Relates to MDAI
Regulatory Pathways: MDAI products must navigate complex regulatory frameworks. The UKCA pathway is being streamlined to prioritize innovative technologies like AI in healthcare https://www.gov.uk/government/news/mhra-announces-proposals-to-improve-access-to-worlds-best-medical-devices-for-patients-and-to-boost-economic-growth-in-britains-med-tech-sector

Market Access: Early traction implies that MDAI solutions are beginning to be used in real-world settings, which is crucial for validating their utility and building trust.

Economic Validation: Health economics data is essential for MDAI adoption. It helps justify reimbursement, informs policy decisions, and proves that AI tools can improve outcomes while reducing costs.

🧬 Bigger Picture
This kind of statement is often used in investor decks or strategic roadmaps to signal that:

The regulatory environment is becoming more favorable for MDAI.

There’s growing clinical and commercial interest.

Evidence is being gathered to support broader adoption.

If you're evaluating an MDAI product or strategy, this kind of language is a green flag that things are moving in the right direction. Want to dive deeper into how UKCA is evolving to support AI in healthcare?

Nah, I'm a believer now or as this author put's it (in this human journey),.. "the continuation of a long miracle, made possible only because people embraced disruption. Humanity may find it's intelligence surpassed."
https://www.economist.com/leaders/2025/07/24/the-economics-of-superintelligence

I bot a thousand share a while back. Wish I had bot 10X that. Good chance FDA is going to give the go ahead.

Spectral AI (MDAI) shares gained 17%. The company said Monday it submitted its De Novo 510k marketing clearance application to the US Food and Drug Administration for the DeepView System's use in burn care settings, including emergency departments.

Load uo

MDAI.................https://stockcharts.com/h-sc/ui?s=MDAI&p=W&b=5&g=0&id=p86431144783

Still here and adding dips, this will be a mega runner

MDAI..................................https://stockcharts.com/h-sc/ui?s=MDAI&p=W&b=5&g=0&id=p86431144783

MDAI..........................https://stockcharts.com/h-sc/ui?s=MDAI&p=W&b=5&g=0&id=p86431144783

MDAI....................................https://stockcharts.com/h-sc/ui?s=MDAI&p=W&b=5&g=0&id=p86431144783

$MDAI risk of being delisted explains manipulative pump .

The Company is not currently in compliance with the continued listing requirements for The Nasdaq Stock Market. If the Company does not regain compliance and continueto meet the continued listing requirements, the Common Stock may be delisted, which could affect the market price and liquidity for theCompany’s Common Stock and reduce the Company’s ability to raise additional capital. On June 3, 2024, the Company receiveda letter from the Listing Qualifications Staff of the Nasdaq Stock Market, LLC (“Nasdaq”) that the Company was not in compliancewith the requirement of Rule 5550(b)(2) relating to the maintenance of a minimum market value of its listed securities of $35.0 millionfor the last 31 consecutive business days. Pursuant to Nasdaq Listing Rule 5810(c)(3)(C), the Company has 180 calendar days from receiptof a notice from Nasdaq (the “Compliance Period”), to regain compliance with the market value of listed securities requirement.If at any time before December 2, 2024, the closing market capitalization of the Company’s Common Stock closes at or above $35.0million for a minimum of 10 consecutive business days, subject to Nasdaq’s discretion to extend this period pursuant to Nasdaq ListingRule 5810(c)(3)(G) to 20 consecutive business days, Nasdaq will provide written notification that the Company has achieved compliancewith the minimum market capitalization requirement, and the matter would be resolved. If the Company does not regain compliance duringthe review period ending December 2, 2024, then Nasdaq may grant the Company a second 180 calendar day period to regain compliance, providedthe Company meets the continued listing requirement for all other initial listing standards for the Nasdaq, other than the minimum market value of listed securities requirement, and notifies Nasdaq of its intent to cure the deficiency.

Although alternative public and private transaction structures may be available, these may require additional time and cost, may impose operational restrictions onthe Company, and may not be available on attractive terms. The Company’s inability to continue to raise capital with its CommonStock as listed on Nasdaq will harm its business, financial condition and results of operations, and will likely cause the Company’sstock value to further decline.

MDAI watchlist 

Making a nice move up today !!

The company will end up being worth a lot more than a 40 cent pump. Loading to hold here

$1.40 Return of founder worth a .40 cent pump

pectral AI, Inc. Announces Return of Founder Dr. J. Michael DiMaio as Chairman of the Board of Directors

Source: GlobeNewswire Inc.

Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that the Company's Founder, Dr. J. Michael DiMaio, has been named Chairman of the Board of Directors.
“Our Board of Directors welcomes Dr. DiMaio back to the role of Spectral AI's Chairman. Given our needs for the future, the Board concluded it was clear Dr. DiMaio’s expertise, leadership style, and deep understanding of our industry and the DeepView® System, paired with his deep commitment to patient care and our employees, make him the right person to lead Spectral AI’s next stage of growth,” said Richard Cotton, current Chairman of the Company’s Board of Directors. “I look forward to supporting him and the rest of the Board as they seize the opportunities ahead.” Mr. Cotton will remain on the Board and serve as the head of the Company’s Audit Committee and Lead Independent Director.

Pump me

MDAI...............................https://stockcharts.com/h-sc/ui?s=MDAI&p=W&b=5&g=0&id=p86431144783

MDAI new 52 week low

MDAI new 52 week low

The global market potential for Spectral AI’s Deep View system and MSI technology is vast, spanning multiple high-growth sectors including medical diagnostics, digital health, wound care, military applications, and cosmetics. Assuming clinical validation, this technology could achieve wide-scale adoption within a decade, driven by its versatility, accuracy, non-invasiveness, and ability to integrate with AI for personalized treatment plans. With the development of lower-cost, handheld devices, the market reach could expand dramatically, bringing MSI technology to a global audience across both clinical and consumer sectors.

MDAI new 52 week low

"Spectral AI Supports Naked Short Selling Inquiry
June 24 2024 - 8:00AM

Alert
Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that it has provided support to Nasdaq and the state securities authorities in Florida, Louisiana and Texas to bring to their attention potential market manipulation of the Company’s common stock, primarily in the form of naked short selling.
This inquiry is being led by Erich Spangenberg, a member of the Board of Directors and the Company’s largest shareholder.

Naked short selling is a practice in which shares are sold without first being borrowed or ensuring that they can be borrowed. This creates an artificial selling pressure and allows traders to artificially drive down prices at the expense of retail investors. The practice is generally illegal pursuant to Securities and Exchange Commission (“SEC”) Regulation SHO.

“As detailed in the Company’s SEC filing today, a simple examination of our shareholder lists we obtained from reliable authorities clearly shows that our public float has been artificially increased by over 40% as a result of what I believe is illegal naked shorting,” said Mr. Spangenberg. “We recognize and appreciate Nasdaq’s commitment to ensuring market transparency and integrity, and its mission to protect the interests of investors. It is in this spirit that we look forward to collaborating with all relevant authorities to address instances of potentially illegal naked short selling in our stock, strengthen compliance, and protect our investors.” ...
https://ih.advfn.com/p.php?pid=nmona&article=94090454

MDAI under $2

Funny that the tape here is always on the low side of the spread and different than Fidelity and Schwab.

Looks to be joining the Russel micro cap index

Oof then busted right through

Strong buying off the 20ema

So undervalued!!! Insiders were very smart to buy many shares at these levels!

$MDAI when least expected this stock will explode! Not like an AMC or GME but on real fundamentals. It wont look back. To many reasons to get into in this forum so do your DD and you should figure out why. Just yesterday huge insider buys! All- time lows.

Clock ticking here some big upside coming